Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
Rhea-AI Summary
Agios (Nasdaq: AGIO) reported Phase 2b results for tebapivat in lower-risk myelodysplastic syndromes (LR-MDS). The trial did not meet the predefined threshold for transfusion independence, and Agios will not advance tebapivat in LR-MDS, though it remained well tolerated with no new safety signals observed.
AI-generated analysis. Not financial advice.
Positive
- Tebapivat showed biological activity in LR-MDS despite missing advancement threshold
- Safety profile favorable with no new safety signals across all dose levels
- Ongoing tebapivat development in sickle cell disease with Phase 2 topline data expected 2H 2026
Negative
- Phase 2b LR-MDS trial did not meet predefined advancement threshold
- Agios will not advance tebapivat for LR-MDS indication
News Market Reaction – AGIO
On the day this news was published, AGIO declined 3.35%, reflecting a moderate negative market reaction. This price movement removed approximately $63M from the company's valuation, bringing the market cap to $1.81B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AGIO gained 6.29% while peers DNLI, IRON, TVTX, APGE and FOLD showed smaller positive moves (up to 4.2%) and did not appear in momentum scanners, indicating a stock-specific reaction rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 22 | EU thalassemia approval | Positive | -2.3% | EU marketing authorisation for PYRUKYND via Avanzanite partnership in thalassemia. |
| May 22 | EU approval detail | Positive | -2.3% | PYRUKYND approved across EU for broad adult thalassemia population with orphan status. |
| May 12 | sNDA for SCD | Positive | +1.5% | Submission of sNDA seeking U.S. accelerated approval of mitapivat in sickle cell disease. |
| May 12 | EHA 2026 datasets | Positive | +1.5% | Announcement of extensive mitapivat data presentations at EHA 2026 and investor webcast. |
| Apr 29 | Q1 2026 earnings | Neutral | +13.1% | Q1 2026 results with higher mitapivat revenue, net loss, and strong cash balance update. |
Recent positive regulatory and data milestones have often seen mixed reactions, with EU approval news sold off but clinical and earnings updates generally bought.
Over the past months, Agios has focused on expanding mitapivat’s rare disease franchise. On Apr 29, Q1 2026 results highlighted $20.7M worldwide mitapivat revenue and a $1.0B cash position, with shares rising 13.1%. Early May brought an sNDA submission for sickle cell disease and EHA 2026 data plans, linked to a 1.54% gain. By May 22, EU approval of PYRUKYND for thalassemia coincided with a -2.26% move, showing that strong regulatory wins have not always produced sustained upside.
Regulatory & Risk Context
The company has an effective automatic shelf registration on Form S-3ASR filed on 2026-02-12, allowing it to issue various securities over time for general corporate purposes, including R&D, commercialization, acquisitions or investments, and potential debt repayment or refinancing.
Market Pulse Summary
This announcement confirms that tebapivat will not advance in lower‑risk MDS after its Phase 2b trial failed to meet a predefined efficacy threshold, though safety remained acceptable. The update shifts attention toward tebapivat’s development in sickle cell disease, with topline Phase 2 data expected in the second half of 2026. Recent history shows Agios balancing pipeline progress with financial losses, so investors may watch future trial readouts, regulatory milestones and funding decisions closely.
Key Terms
phase 2b medical
myelodysplastic syndromes medical
pyruvate kinase medical
transfusion independence medical
sickle cell disease medical
safety signals medical
open-label medical
multicenter medical
AI-generated analysis. Not financial advice.
- Results did not meet predefined threshold to support further development in LR-MDS
- Tebapivat was well tolerated, with no new safety signals observed
CAMBRIDGE, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that it will not advance tebapivat, a next-generation oral pyruvate kinase (PK) activator, in lower-risk myelodysplastic syndromes (LR-MDS). This decision follows results from its Phase 2b trial that did not meet the company’s predefined threshold to support further development in this indication.
The open-label, multicenter, 24-week dose-finding trial evaluated once-daily tebapivat at 10 mg, 15 mg, and 20 mg in 65 patients with LR-MDS and anemia, representing a heavily pretreated, heterogeneous population. The primary endpoint was transfusion independence, defined as eight consecutive weeks without a transfusion during the 24-week treatment period. While tebapivat demonstrated evidence of biological activity, clinical benefit was not observed in a sufficient proportion of patients or subgroup of patients to meet the company’s predefined threshold for advancement in LR-MDS. Tebapivat was well tolerated across all dose levels, with no new safety signals identified.
“The results from the Phase 2b trial underscore the biological complexity of lower-risk myelodysplastic syndromes and the challenges of identifying patients most likely to benefit. On behalf of the entire Agios team, I want to extend our sincere gratitude to the patients, caregivers, investigators, and broader community who made this research possible,” said Sarah Gheuens, M.D., Ph.D., Chief Medical Officer and Head of R&D, Agios. “PK activation remains a clinically validated mechanism, and we continue to see significant potential for tebapivat as a next-generation medicine in sickle cell disease. We look forward to sharing topline data from this Phase 2 trial in the second half of 2026.”
About Tebapivat
Tebapivat is a next-generation oral pyruvate kinase (PK) activator designed to provide optimized clinical benefits for patients with rare hematologic diseases. It is structurally differentiated by its potent dual activation of the PKR and PKM2 isoforms (or variants) of the PK enzyme, which are expressed in red blood cells. Clinical pharmacology data supports once-daily dosing of tebapivat, without the need for a dose taper. Tebapivat is currently being evaluated in a Phase 2 trial for the treatment of sickle cell disease, with topline data anticipated in the second half of 2026.
About Agios: Fueled by Connections to Transform Rare Diseases™
At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities – collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit www.agios.com and follow us on LinkedIn and X.
Available Information about Agios
To achieve broad dissemination, Agios may disclose information to the public through a variety of disclosure channels including press releases, SEC filings, and public conference calls and webcasts. Some of the information distributed through these disclosure channels may be considered material information. Investors and others should note that Agios plans to use its website (www.agios.com) as a distribution channel to announce and give notice of Agios’ upcoming events and presentations (including, but not limited to, presentations at medical or healthcare conferences). Such information, which may be deemed material, will be available on the Investors section of the company’s website under the “Events & Presentations” tab. In addition, you may sign up to automatically receive email alerts about Agios’ upcoming events and presentations (“Calendar Alerts”) by visiting the “Email Alerts” option under the “IR Resources” tab of the Investors section of the company’s website and submitting your email address.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of tebapivat; and the potential benefits of Agios’ strategic plans and focus. The words “anticipate,” “expect,” “goal,” “hope,” “milestone,” “plan,” “potential,” “possible,” “strategy,” “will,” “vision,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios’ current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios’ product candidates will successfully continue. There can be no guarantee that any positive developments in Agios’ business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including, without limitation: risks and uncertainties related to the impact of pandemics or other public health emergencies to Agios’ business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Agios’ results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios’ ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios’ ability to establish and maintain key collaborations; uncertainty regarding any royalty payments related to the sale of its oncology business or any milestone or royalty payments related to its in-licensing of AG-236, and the uncertainty of the timing of any such payments; uncertainty of the results and effectiveness of the use of Agios’ cash and cash equivalents; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Agios’ public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contacts:
Investor Contact
Morgan Sanford, Vice President, Investor Relations
Agios Pharmaceuticals
morgan.sanford@agios.com
Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
eamonn.nolan@agios.com
